macro

Novartis sees 5% annual sales growth through 2031

Novartis set mid-term targets of about 5% yearly sales growth at constant currency through 2031 and raised peak sales forecasts for three key drugs.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

Swiss drugmaker Novartis on Thursday updated its mid-term financial targets. It now expects net sales to rise about 5% a year at constant currencies from 2026 through 2031. The company had previously guided to growth of 5% to 6% over 2025 to 2030, so the new figure sits at the lower end of that earlier range, according to Reuters. The targets were released ahead of the company's annual investor event in London.

Novartis also lifted peak sales estimates for Kesimpta, Scemblix and Leqvio. Kesimpta's peak is now seen at $8 billion, up from $6 billion, while Scemblix and Leqvio each rise to $5 billion from $4 billion. The company says it has nine marketed products with peak sales potential of $3 billion to $10 billion, plus 10 candidates in late-stage development. It also reaffirmed its aim of returning to a core operating profit margin above 40% by 2029, as it had indicated before.

why it matters

For markets, these guidance changes offer a read on the outlook of a major drugmaker. Growth at the lower end of the earlier range may be seen cautiously, but higher peak sales forecasts for key drugs and the unchanged margin goal point to management confidence in its portfolio. For the healthcare sector, this supports the view of large pharma companies as steady, though how the shares trade will depend on broader investor sentiment.

market impact

Novartis: mixed signals, with cautious growth targets offset by higher drug sales forecasts

  • Novartis shares mixed — growth guidance at the lower end of the range against raised peak sales forecasts for key drugs

tags

instruments

NovartisSMIKesimptaScemblixLeqvio

sources

  1. Novartis targets 5% annual sales growth through 2031 — Reuters, 19 November 2026 at 06:21 UTC
  2. Novartis Sees Sales Growth Through 2031 — Dow Jones Newswires, 19 November 2026 at 06:24 UTC
  3. Novartis Sees Sales Growth Through 2031 — Dow Jones Newswires, 19 November 2026 at 06:39 UTC
  4. Novartis narrows mid-term annual sales growth target to 5% through 2031 — Reuters, 19 November 2026 at 06:51 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗